Eleven Biotherapeutics
215 First Street
Suite 400
Cambridge
Massachusetts
02142
United States
Tel: 617-871-9911
Fax: 617-858-0911
Website: http://www.elevenbio.com/
Email: info@elevenbio.com
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. Eleven’s therapeutic approach is based on the role of cytokines in diseases of the eye, the Company’s understanding of the structural biology of cytokines and the Company’s ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects.YEAR FOUNDED:
2000
LEADERSHIP:
Founder: Reza Dana, K. Christopher Garcia, Greg Verdine, Casey Weaver, K. Dane Wittrup
CEO: Abbie Celniker
CMO (Medical): Michael Goldstein
JOBS:
Please click here for Eleven Biotherapeutics.
120 articles about Eleven Biotherapeutics
-
Cambridge's Eleven Bio Pink Slips 70% of Workforce in Restructuring
6/24/2016
-
Struggling Eleven Bio Forges Deal Worth $270 Million with Pharma Giant Roche
6/13/2016
-
Eleven Bio Announces Investigational New Drug Application Submission To Initiate Clinical Trials Of EBI-031 For Ocular Diseases
6/13/2016
-
Eleven Biotherapeutics Reports First Quarter 2016 Financial Results
5/5/2016
-
Eleven Biotherapeutics To Present Data At The Association for Research in Vision & Ophthalmology 2016 Annual Meeting
4/29/2016
-
Eleven Biotherapeutics Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Strategic Update
3/24/2016
-
Struggling Eleven Biotherapeutics Gets Delisting Notice from Nasdaq After Back-to-Back Clinical Trial Failures
3/11/2016
-
Albumedix And Eleven Biotherapeutics Announce Albumin Variant Technology Agreement
1/26/2016
-
Eleven Biotherapeutics Stock Plunges on Yet Another Failed Clinical Trial
1/19/2016
-
Eleven Biotherapeutics Reports Third Quarter 2015 Financial Results
11/4/2015
-
Eleven Biotherapeutics To Report Third Quarter 2015 Financial Results On November 4, 2015
10/27/2015
-
Eleven Biotherapeutics Completes Enrollment In Pivotal Phase III Study Of Isunakinra (EBI-005) In Patients With Allergic Conjunctivitis
10/15/2015
-
Eleven Biotherapeutics Announces Promotions Of Gary Sternberg, MD, MBA To Chief Business Officer And John Mccabe, CPA To Senior Vice President, Finance
9/1/2015
-
Eleven Biotherapeutics To Present At NewsMakers In The Biotech Industry Conference
8/31/2015
-
Eleven Biotherapeutics Reports Second Quarter 2015 Financial Results
8/13/2015
-
Eleven Biotherapeutics Announces First Patients Dosed With EBI-005 In Phase 3 Study In Patients With Moderate To Severe Allergic Conjunctivitis
8/12/2015
-
Eleven Biotherapeutics To Report Second Quarter 2015 Financial Results On August 13, 2015
8/4/2015
-
Eleven Biotherapeutics CFO Decamps for Aegerion in Executive Suite Shuffle
6/25/2015
-
Eleven Biotherapeutics Stock Nosedives 80% Premarket as Eye Drug Flunks Phase III Test
5/19/2015
-
Eleven Biotherapeutics Announces Top-Line Results From Pivotal Phase 3 Study Of EBI-005 In Patients With Moderate To Severe Dry Eye Disease
5/18/2015